Monopar Therapeutics Q3 2025 Earnings Report

Monopar Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.48
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Monopar Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Monopar Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: Before Market Opens
• Conference Call Date: Friday, November 7, 2025
• Conference Call Time: 4:00PM ET

Monopar Therapeutics (NASDAQ:MNPR), Inc. is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. Monopar’s lead programs employ its PRIT platform to address both hematologic malignancies and solid tumors, and the company is also exploring antibody-drug conjugate approaches to expand its immunotherapeutic offerings. Through these efforts, Monopar seeks to deliver targeted, high-potency treatments that can overcome resistance and improve patient outcomes.

Founded in 2018 and headquartered in Newton, Massachusetts, Monopar Therapeutics has established research collaborations and licensing agreements to advance its proprietary technologies. The company holds global rights to its PRIT platform, which was initially developed through academic partnerships, and maintains research operations in key U.S. life-science clusters. Monopar continues to strengthen its development capabilities through strategic collaborations with academic institutions and contract research organizations.

Monopar is led by a management team with extensive experience in oncology drug development, radiopharmaceutical manufacturing and clinical operations. The leadership team combines scientific expertise and industry know-how to advance the company’s pipeline and navigate regulatory pathways. Together, they are working to bring next-generation targeted therapies to patients with high-need cancers.